Landos Biopharma's market cap is currently ―. The company's EPS TTM is $-3.492; its P/E ratio is -6.23; Landos Biopharma is scheduled to report earnings on May 10, 2024, and the estimated EPS forecast is $-1.00. See an overview of income statement, balance sheet, and cash flow financials.

	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22
Income Statement	-
Total Revenue	-	-	-	-	$ 0.00
Gross Profit	-	-	-	-	-
EBIT	$ -6.52M	$ -3.92M	$ -6.48M	$ -7.78M	$ -7.83M
EBITDA	$ -6.52M	$ -3.91M	$ -6.45M	$ -7.68M	$ -7.83M
Net Income Common Stockholders	$ -5.86M	$ -3.92M	$ -5.90M	$ -5.16M	$ -7.90M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	$ 42.47M	$ 44.74M	$ 50.01M	$ 44.40M	$ 47.99M
Total Assets	$ 43.23M	$ 46.28M	$ 51.18M	$ 45.25M	$ 49.49M
Total Debt	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Net Debt	$ -42.47M	$ -44.74M	$ -50.01M	$ -44.40M	$ -47.99M
Total Liabilities	$ 5.57M	$ 3.02M	$ 4.16M	$ 6.12M	$ 5.47M
Stockholders Equity	$ 37.71M	$ 43.25M	$ 46.98M	$ 39.16M	$ 44.01M
Cash Flow	-
Free Cash Flow	$ -2.23M	$ -5.11M	$ -8.17M	$ -3.64M	$ -7.57M
Operating Cash Flow	$ -2.23M	$ -5.11M	$ -8.17M	$ -3.70M	$ -7.57M
Investing Cash Flow	$ 634.00K	$ 3.97M	$ 3.10M	$ 11.47M	$ 17.21M
Financing Cash Flow	-	$ -99.00K	$ 13.67M	-	$ 0.00

Currency in USD

Landos Biopharma Earnings and Revenue History

Income Statement >

Landos Biopharma Debt to Assets

Balance Sheet >

Landos Biopharma Cash Flow

Cash Flow >

Landos Biopharma Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing